Blueprint Medicines(BPMC) - 2024 Q4 - Annual Results

-- Anticipate global AYVAKIT net product revenue of approximately $680 million to$710 million in 2025, representing a 45% percent year-over-year growth at the midpoint – -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve$2 billion in revenue by 2030 -- EXHIBIT 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including$144.1 mi ...